Promotional material

The UK: your partner for genomics and personalised medicine

This prospectus describes genomics and personalised medicine, why the UK is a leading player and how overseas partners can work with the UK.

• From: Department for International Trade, Department of Health and Social Care and George Freeman MP
• Published: 9 March 2016

This was published under the 2015 to 2016 Cameron Conservative government

This publication was withdrawn on 2 December 2020

Department for International Trade withdrew this publication because it was out of date.

Documents

Genomics and personalised medicine: how partnership with the UK can transform healthcare

Ref: UKTI/2015/92

HTML

[Withdrawn] Genomics and personalised medicine: how partnership with the UK can transform healthcare

Ref: UKTI/15/92

PDF, 2.99 MB, 13 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email govuk-feedback@digital.cabinet-office.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The 100,000 Genomes Project, led by Genomics England, is sequencing the genomes of 100,000 NHS patients and combining this with NHS data.

This ground breaking work highlights the world-leading position the UK holds in genomics. We are already at an advanced stage of a systematic long-term plan for integrating genomic and personalised medicine into the day-to-day delivery of healthcare.

The NHS will be the world’s first healthcare system to launch a genomics medicine service.

International interest in the UK’s approach to genomics and personalised medicine is growing. There is huge potential for this expertise to be shared with governments, healthcare providers and commercial companies.

This prospectus explains what genomics and personalised medicine are, how they can be applied, and why the UK is at the forefront of this field.

The UK is investing heavily to set up the necessary infrastructure and levels of service integration to deliver population wide benefits from genomics.

We are in the process of creating an unparalleled end-to-end service, integrating every step of the genomic pathway to maximise patient benefit.

You can draw on this knowledge and experience to invest in the facilities and services needed to optimise these benefits.

Genomics is complex field, but finding suitable commercial partners in the UK need not be. The simplest way to access this expertise is through Healthcare UK, UK government’s specialists in international healthcare partnership working.

This was published originally by UK Trade and Investment which has since moved to the Department for International Trade (DIT).

Published 9 March 2016